-
1 Comment
CStone Pharmaceuticals is currently in a long term uptrend where the price is trading 42.3% above its 200 day moving average.
From a valuation standpoint, the stock is 92.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Its net income has increased by 48.7% to $-550M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.6% to $-330M since the same quarter in the previous year.
Based on the above factors, CStone Pharmaceuticals gets an overall score of 4/5.
| ISIN | KYG2588M1006 |
|---|---|
| Exchange | HK |
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 6.5499 |
|---|---|
| Market Cap | 10B |
| PE Ratio | None |
| Beta | 0.04 |
| Dividend Yield | None |
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma. The company's products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2616.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
